UBX - upcoming catalysts - This is not a financial advice!
Most info on the chart.
We might seeing a pullback first before further upmove.
Trade carefully!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.3191 USD
−39.86 M USD
0.00 USD
15.37 M
About Unity Biotechnology, Inc.
Sector
Industry
CEO
Anirvan Ghosh
Website
Headquarters
South San Francisco
Founded
2009
FIGI
BBG00F412FG6
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
UBX - Education/Training ChartSee my comments as shown in the chart and leave any questions or comments below.
This stock is a great learning example of what to look for to spot trends and patterns.
NOTE: I am staying Neutral on this stock as to not give a clue on the potential Target Price.
UNITY Biotechnology Announces Positive Data in Phase 2UBX: Unity Biotechnology, Inc.
2022-08-12 07:00:00 UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
UBX ( NASDAQ BIOTECH PENNY) crushes earnings and news catalystNASDAQ:UBX
and rises over 100 % in premarket, Has a new product
for macular degeneration, a widespread medical problem
affecting vision in the elderly which is increasing
in incidence. The earning beat was significant.
Chart demonstrates the uptrend and midrange
RSI but does not show today's prem
long Term trade PT 6+ Hello, just sharing a idea of a company I ran across that looks like its in falling wedge formation with positive earnings to boot and at a all time low.
Invest like Jeff Bezos & Peter Thiel, buy longevity stocks.Have you ever wondered what you like to buy with your money if you were super-rich?
Maybe buy something that would make you live longer?
Well the problem is that doesn't really exist yet, which is why people are/should invest in this company 😃
www.cnbc.com
There are different longevity-related
$UBX Long-Term Target $18.90Unity Biotechnology is a pharmaceutical company focused on creating a drug that will extend the years people can live unburdened by disease. This drug has shown a great deal of promise and is currently in phase two clinical trials. As the trials progress, we can expect the price to rise dramatically
Anti-aging biotech is looking super juicy meow meow style!I don't invest in Pharma, and this isn't Pharma! As I understand it, the company is making implants to help counter the aging process. Very future, very cool!
I think this could be a very good week for this stock!
As always, this is not investment advice!
UBX BuyyyUBX is hitting styrong support and we should see a bounce for the next few weeks. This stock has huge potential.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UBX is 0.9598 USD — it has decreased by −1.04% in the past 24 hours. Watch Unity Biotechnology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unity Biotechnology, Inc. stocks are traded under the ticker UBX.
UBX stock has fallen by −13.53% compared to the previous week, the month change is a −17.97% fall, over the last year Unity Biotechnology, Inc. has showed a −42.87% decrease.
We've gathered analysts' opinions on Unity Biotechnology, Inc. future price: according to them, UBX price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch UBX chart and read a more detailed Unity Biotechnology, Inc. stock forecast: see what analysts think of Unity Biotechnology, Inc. and suggest that you do with its stocks.
UBX stock is 5.09% volatile and has beta coefficient of 0.42. Track Unity Biotechnology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Unity Biotechnology, Inc. there?
Today Unity Biotechnology, Inc. has the market capitalization of 16.17 M, it has decreased by −10.53% over the last week.
Yes, you can track Unity Biotechnology, Inc. financials in yearly and quarterly reports right on TradingView.
Unity Biotechnology, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
UBX earnings for the last quarter are −0.38 USD per share, whereas the estimation was −0.40 USD resulting in a 5.84% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Unity Biotechnology, Inc. earnings.
Unity Biotechnology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
UBX net income for the last quarter is −6.48 M USD, while the quarter before that showed −5.28 M USD of net income which accounts for −22.77% change. Track more Unity Biotechnology, Inc. financial stats to get the full picture.
No, UBX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 19.00 employees. See our rating of the largest employees — is Unity Biotechnology, Inc. on this list?
Like other stocks, UBX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unity Biotechnology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unity Biotechnology, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unity Biotechnology, Inc. stock shows the sell signal. See more of Unity Biotechnology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.